Biological characterization of a novel class of toll-like receptor 7 agonists designed to have reduced systemic activity

British Journal of Pharmacology

Volumn 166, Issue 2, 2012, Pages 573-586

  Biffen, M ^a   Matsui, H ^b   Edwards, S ^a   Leishman, A J ^a   Eiho, K ^b   Holness, E ^a   Satterthwaite, G ^a   Doyle, I ^a   Wada, H ^a   Fraser, N J ^a,c   Hawkins, S L ^a   Aoki, M ^b   Tomizawa, H ^b   Benjamin, A D ^a   Takaku, H ^b   McInally, T ^a   Murray, C M ^a  

^a ASTRAZENECA   (United Kingdom)

^b DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^c VERTEX PHARMACEUTICALS   (United States)

Author keywords

allergy; cytokines; lung; mononuclear cells; reporter cell; splenocytes; TLR7

Indexed keywords

2 [3 [(6 AMINO 2 BUTOXY 8 OXO 7H PURIN 9(8H)YL)METHYL]PHENYL]ACETATE; 2 [3 [(6 AMINO 2 BUTOXY 8 OXO 7H PURIN 9(8H)YL)METHYL]PHENYL]ACETIC ACID; 2 [3 [[[3 (6 AMINO 2 BUTOXY 8 OXO 7H PURIN 9(8H)YL)PROPYL][3 (DIMETHYLAMINO)PROPYL]AMINO]PHENYL]ACETIC ACID]; ALPHA INTERFERON; AZ 12441970; AZ 12443988; INTERLEUKIN 5; METHYL 2 [3 [[[3 (6 AMINO 2 BUTOXY 8 OXO 7H PURIN 9(8H)YL)PROPYL][3 (DIMETHYLAMINO)PROPYL]AMINO]PHENYL]ACETATE]; RESIQUIMOD; SM 324405; SM 324406; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 7 AGONIST; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG IDENTIFICATION; DRUG METABOLISM; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; EMBRYO; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RAT; RESPIRATORY TRACT ALLERGY; SPLEEN CELL;

ACETATES; ADENINE; ANIMALS; ANTI-ALLERGIC AGENTS; BRONCHOALVEOLAR LAVAGE FLUID; CELLS, CULTURED; CYTOKINES; DISEASE MODELS, ANIMAL; DOGS; FEMALE; GENE EXPRESSION REGULATION; HEK293 CELLS; HUMANS; LEUKOCYTES, MONONUCLEAR; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; OVALBUMIN; RATS; RESPIRATORY HYPERSENSITIVITY; RNA, MESSENGER; SPLEEN; TOLL-LIKE RECEPTOR 7;

EID: 84859313808     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01790.x     Document Type: Article

References (34)

1. Alexander SPH, Mathie A, Peters JA, (2011). Guide to Receptors and Channels (GRAC), 5th Edition. Br J Pharmacol 164 (Suppl. 1): S1-S324.
2. Braun-Fahrlander C, Riedler J, Herz U, Eder W, Waser M, Grize L, et al,. (2002). Environmental exposure to endotoxin and its relation to asthma in school-age children. N Engl J Med 347: 869-877.
3. Camateros P, Tamaoka M, Hassan M, Marino R, Moisan J, Marion D, et al,. (2007). Chronic asthma-induced airway remodeling is prevented by toll-like receptor-7/8 ligand S28463. Am J Respir Crit Care Med 175: 1241-1249. (Pubitemid 46905749)
4. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C, (2004). Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303: 1529-1531. (Pubitemid 38314425)
5. Dudek AZ, Yunis C, Harrison LI, Kumar S, Hawkinson R, Cooley S, et al,. (2007). First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer. Clin Cancer Res 13: 7119-7125. (Pubitemid 350276897)
6. Fidock MD, Souberbielle BE, Laxton C, Rawal J, Delpuech-Adams O, Corey TP, et al,. (2011). The innate immune response, clinical outcomes, and ex vivo HCV antiviral efficacy of a TLR7 agonist (PF-4878691). Clin Pharmacol Ther 89: 821-829.
7. Fili L, Ferri S, Guarna F, Sampognaro S, Manuelli C, Liotta F, et al,. (2006). Redirection of allergen-specific TH2 responses by a modified adenine through Toll-like receptor 7 interaction and IL-12/IFN release. J Allergy Clin Immunol 118: 511-517. (Pubitemid 44160724)
8. Gorden KB, Gorski KS, Gibson SJ, Kedl RM, Kieper WC, Qiu X, et al,. (2005). Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J Immunol 174: 1259-1268.
9. Guiducci C, Coffman RL, Barrat FJ, (2009). Signalling pathways leading to IFN-alpha production in human plasmacytoid dendritic cell and the possible use of agonists or antagonists of TLR7 and TLR9 in clinical indications. J Intern Med 265: 43-57.
10. Hanten JA, Vasilakos JP, Riter CL, Neys L, Lipson KE, Alkan SS, et al,. (2008). Comparison of human B cell activation by TLR7 and TLR9 agonists. BMC Immunol 9: 39.
11. Haux JE, Quistad GB, Casida JE, (2000). Phosphobutyrylcholinesterase: phosphorylation of the esteratic site of butyrylcholinesterase by ethephon [(2-chloroethyl)phosphonic acid] dianion. Chem Res Toxicol 13: 646-651. (Pubitemid 30491126)
12. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, et al,. (2002). Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 3: 196-200. (Pubitemid 34141451)
13. Holgate ST, (2008). Pathogenesis of asthma. Clin Exp Allergy 38: 872-897.
14. Horsmans Y, Berg T, Desager JP, Mueller T, Schott E, Fletcher SP, et al,. (2005). Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology 42: 724-731. (Pubitemid 41233667)
15. Huber JP, Ramos HJ, Gill MA, Farrar JD, (2010). Cutting edge: Type I IFN reverses human Th2 commitment and stability by suppressing GATA3. J Immunol 185: 813-817.
16. Isobe Y, Tobe M, Ogita H, Kurimoto A, Ogino T, Kawakami H, et al,. (2003). Synthesis and structure-activity relationships of 2-substituted-8- hydroxyadenine derivatives as orally available interferon inducers without emetic side effects. Bioorg Med Chem 11: 3641-3647. (Pubitemid 36952262)
17. Iwasaki A, Medzhitov R, (2010). Regulation of adaptive immunity by the innate immune system. Science 327: 291-295.
18. Jurk M, Heil F, Vollmer J, Schetter C, Krieg AM, Wagner H, et al,. (2002). Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat Immunol 3: 499. (Pubitemid 34669818)
19. Kurimoto A, Hashimoto K, Nakamura T, Norimura K, Ogita H, Takaku H, et al,. (2010). Synthesis and biological evaluation of 8-oxoadenine derivatives as toll-like receptor 7 agonists introducing the antedrug concept. J Med Chem 53: 2964-2972.
20. Latz E, Schoenemeyer A, Visintin A, Fitzgerald KA, Monks BG, Knetter CF, et al,. (2004). TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol 5: 190-198. (Pubitemid 38208361)
21. Lee HJ, Soliman MR, (1982). Anti-inflammatory steroids without pituitary-adrenal suppression. Science 215: 989-991. (Pubitemid 12154212)
22. Lund JM, Alexopoulou L, Sato A, Karow M, Adams NC, Gale NW, et al,. (2004). Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci U S A 101: 5598-5603. (Pubitemid 38481202)
23. Pearce N, Ait-Khaled N, Beasley R, Mallol J, Keil U, Mitchell E, et al,. (2007). Worldwide trends in the prevalence of asthma symptoms: phase III of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax 62: 758-766.
24. Pockros PJ, Guyader D, Patton H, Tong MJ, Wright T, McHutchison JG, et al,. (2007). Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies. J Hepatol 47: 174-182. (Pubitemid 47021257)
25. Reiter MJ, Testerman TL, Miller RL, Weeks CE, Tomai MA, (1994). Cytokine induction in mice by the immunomodulator imiquimod. J Leukoc Biol 55: 234-240. (Pubitemid 24066348)
26. Romagnani S, (2004). The increased prevalence of allergy and the hygiene hypothesis: missing immune deviation, reduced immune suppression, or both? Immunology 112: 352-363. (Pubitemid 38859512)
27. Sasai M, Linehan MM, Iwasaki A, (2010). Bifurcation of Toll-like receptor 9 signaling by adaptor protein 3. Science 329: 1530-1534.
28. Takeda K, Kaisho T, Akira S, (2003). Toll-like receptors. Annu Rev Immunol 21: 335-376. (Pubitemid 37174535)
29. Testerman TL, Gerster JF, Imbertson LM, Reiter MJ, Miller RL, Gibson SJ, et al,. (1995). Cytokine induction by the immunomodulators imiquimod and S-27609. J Leukoc Biol 58: 365-372.
30. Van Rijt LS, Kuipers H, Vos N, Hijdra D, Hoogsteden HC, Lambrecht BN, (2004). A rapid flow cytometric method for determining the cellular composition of bronchoalveolar lavage fluid cells in mouse models of asthma. J Immunol Methods 288: 111-121. (Pubitemid 38739257)
31. Vultaggio A, Nencini F, Fitch PM, Fili L, Maggi L, Fanti P, et al,. (2009). Modified adenine (9-benzyl-2-butoxy-8-hydroxyadenine) redirects Th2-mediated murine lung inflammation by triggering TLR7. J Immunol 182: 880-889.
32. Wagner TL, Ahonen CL, Couture AM, Gibson SJ, Miller RL, Smith RM, et al,. (1999). Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod. Cell Immunol 191: 10-19. (Pubitemid 29054962)
33. Wan L, Lin CW, Lin YJ, Sheu JJ, Chen BH, Liao CC, et al,. (2008). Type I IFN induced IL1-Ra expression in hepatocytes is mediated by activating STAT6 through the formation of STAT2: STAT6 heterodimer. J Cell Mol Med 12: 876-888. (Pubitemid 351718067)
34. Wu CC, Hayashi T, Takabayashi K, Sabet M, Smee DF, Guiney DD, et al,. (2007). Immunotherapeutic activity of a conjugate of a Toll-like receptor 7 ligand. Proc Natl Acad Sci U S A 104: 3990-3995. (Pubitemid 47181566)